ZOETIS (ZTS) Earnings Date & Reports

Key Takeaways

• Zoetis is scheduled to report third-quarter 2026 results before the market opens on Thursday, November 5, 2026, followed by a conference call at 8:30 a.m. ET.
• Wall Street consensus points to earnings of roughly $1.51 per share on revenue near $2.30 billion, both below the prior-year quarter's adjusted EPS of $1.70 and revenue of $2.4 billion.
• The company lowered its full-year 2026 outlook in August, guiding to revenue of $9.12 billion to $9.32 billion and adjusted EPS of $6.15 to $6.25.
• Investors will focus on soft U.S. companion animal (pet) demand, declining veterinary clinic visits, and the recovery of the Librela osteoarthritis pain franchise.
• The livestock segment has remained a relative bright spot, delivering double-digit organic growth in recent quarters.

Earnings Context and Why It Matters

Zoetis is the world's largest pure-play animal health company, and its quarterly report offers a broad read on pet-care spending and global protein production. The stock has faced sustained pressure in 2026 after a disappointing first quarter triggered a steep sell-off and prompted management to trim guidance. Since then, weaker U.S. companion animal demand, intense competition in dermatology, and lingering concerns around the Librela osteoarthritis pain product have weighed on sentiment. This report will help investors judge whether those headwinds are stabilizing and whether cost-containment efforts are protecting profitability, making it a pivotal checkpoint for the company's full-year trajectory.

Earnings Expectations

For the third quarter of 2026, analysts expect Zoetis to report earnings per share (EPS, a measure of profit allocated to each share of stock) of approximately $1.51 to $1.52, on revenue of about $2.30 billion. That compares with adjusted EPS of $1.70 and revenue of $2.4 billion in the third quarter of 2025, implying a meaningful year-over-year decline that reflects the company's acknowledged slowdown in parts of its companion animal portfolio.

These estimates are consistent with Zoetis's own updated guidance, which calls for full-year 2026 revenue of $9.12 billion to $9.32 billion and adjusted EPS of $6.15 to $6.25. Management trimmed that outlook in August as U.S. clinic visits softened and competition intensified. Key metrics to watch include U.S. versus international revenue growth, companion animal and livestock segment performance, and adjusted gross margin. Historically, Zoetis shares have reacted sharply to guidance changes, so commentary on the fourth quarter and the 2027 outlook could matter as much as the headline figures.

AI Screener

Tracking earnings catalysts across thousands of names can be time-consuming, which is where Tickeron's AI Screener can help. This AI-powered stock and ETF (exchange-traded fund) discovery tool lets traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of securities using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring names like Zoetis ahead of earnings, it provides a fast way to compare the broader animal health and healthcare landscape.

Market Reaction and Investor Sentiment

Sentiment heading into this report remains cautious. Zoetis shares fell sharply following its first-quarter release in May, when the company cut guidance, and have continued to lag the broader market through 2026. The August second-quarter report added to the gloom after management further reduced its full-year outlook, citing declining U.S. therapeutic visits and aggressive promotional activity in dermatology. As a result, investors enter this print with modest expectations, and the risk appears balanced between further downside on weak pet-care demand and potential relief if results show signs of stabilization. Commentary on Librela, cost savings, and any stabilization in clinic traffic will likely drive the immediate post-earnings move.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should watch several factors that could shape Zoetis's trajectory into 2027. First is the health of the U.S. companion animal business. Declining veterinary therapeutic visits have been a persistent drag, and any evidence that patient starts are stabilizing would be a positive signal. Management has repeatedly pointed to alternative channels such as home delivery and retail, which could offset some clinic weakness.

Second is the osteoarthritis pain franchise. Librela sales fell in prior quarters amid negative social media attention, but the company has said it expects stabilization and a return to growth. Newer long-acting products such as Lenivia, expected to launch in the first half of 2026, could expand the market and improve compliance with less frequent dosing.

Third is the cost and productivity program announced earlier this year. Its ability to protect margins even as revenue growth softens will be closely scrutinized, given the company's "leveraged" profit-and-loss goals. Finally, livestock remains a resilient driver supported by strong protein demand, and continued broad-based growth there would help balance weakness elsewhere. Investors will also listen for any update on the full-year 2026 outlook and early signals for 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations